Lagace TA - Search Results

1

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH. Zhao Z, et al. Among authors: lagace ta. Am J Hum Genet. 2006 Sep;79(3):514-23. doi: 10.1086/507488. Epub 2006 Jul 18. Am J Hum Genet. 2006. PMID: 16909389 Free PMC article.

2

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Zhang DW, et al. Among authors: lagace ta. J Biol Chem. 2007 Jun 22;282(25):18602-18612. doi: 10.1074/jbc.M702027200. Epub 2007 Apr 23. J Biol Chem. 2007. PMID: 17452316 Free article.

3

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

McNutt MC, Lagace TA, Horton JD. McNutt MC, et al. Among authors: lagace ta. J Biol Chem. 2007 Jul 20;282(29):20799-803. doi: 10.1074/jbc.C700095200. Epub 2007 May 29. J Biol Chem. 2007. PMID: 17537735 Free article.

4

Molecular basis for LDL receptor recognition by PCSK9.

Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Kwon HJ, et al. Among authors: lagace ta. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4. Proc Natl Acad Sci U S A. 2008. PMID: 18250299 Free PMC article.

5

Plasma PCSK9 preferentially reduces liver LDL receptors in mice.

Grefhorst A, McNutt MC, Lagace TA, Horton JD. Grefhorst A, et al. Among authors: lagace ta. J Lipid Res. 2008 Jun;49(6):1303-11. doi: 10.1194/jlr.M800027-JLR200. Epub 2008 Mar 19. J Lipid Res. 2008. PMID: 18354138 Free PMC article.

6

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.

McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA. McNutt MC, et al. Among authors: lagace ta. J Biol Chem. 2009 Apr 17;284(16):10561-70. doi: 10.1074/jbc.M808802200. Epub 2009 Feb 17. J Biol Chem. 2009. PMID: 19224862 Free PMC article.

7

Genetic and metabolic determinants of plasma PCSK9 levels.

Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Lakoski SG, et al. Among authors: lagace ta. J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43. doi: 10.1210/jc.2009-0141. Epub 2009 Apr 7. J Clin Endocrinol Metab. 2009. PMID: 19351729 Free PMC article.

8

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Lagace TA, et al. J Clin Invest. 2006 Nov;116(11):2995-3005. doi: 10.1172/JCI29383. J Clin Invest. 2006. PMID: 17080197 Free PMC article.

9

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Lagace TA. Lagace TA. Curr Opin Lipidol. 2014 Oct;25(5):387-93. doi: 10.1097/MOL.0000000000000114. Curr Opin Lipidol. 2014. PMID: 25110901 Free PMC article. Review.

10

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Kosenko T, Golder M, Leblond G, Weng W, Lagace TA. Kosenko T, et al. Among authors: lagace ta. J Biol Chem. 2013 Mar 22;288(12):8279-8288. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11. J Biol Chem. 2013. PMID: 23400816 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page